acetate salt raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-30 and is reviewed periodically as new material appears.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Icaridin (Insect repellent) SSRIs (selective serotonin reuptake inhibitors) Paroxetine Stimulants and nootropics: Methylphenidate Ethylphenidate Pipradrol Desoxypipradrol Histamine 1 (H1) receptor antagonists/inverse agonists: Loratadine Histamine 3 (H3) receptor antagonists/inverse agonists: Pitolisant SERM (selective estrogen receptor modulators) Raloxifene Vasodilators Minoxidil Antipsychotic medications: Droperidol Haloperidol Melperone Mesoridazine Risperidone Thioridazine Opioids: Dipipanone Fentanyl and analogs Loperamide Pethidine (meperidine) Prodine Arylcyclohexylamines: PCP and analogs anticholinergic chemical weapons Ditran N-Methyl-3-piperidyl benzilate (JB-336, BZ) Piperidine is also commonly used in chemical degradation reactions, such as the sequencing of DNA in the cleavage of particular modified nucleotides. Piperidine is also commonly used as a base for the deprotection of Fmoc-amino acids used in solid-phase peptide synthesis. Piperidine is listed as a Table II precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances due to its use (peaking in the 1970s) in the clandestine manufacture of phencyclidine.
== Role in B and T Cell Production and Homeostasis == Reticular cells play a central role in the development and homeostasis of both B and T lymphocytes. Within the lymph node, fibroblastic reticular cells form a 3D network that acts as both a structural outline and communication network for immune signaling. Immune signaling is crucial to survival of the human body. These specific structures allow T cells to migrate efficiently through the lymph node, scanning for antigens presented by dendritic cells while doing so. In the T-cell zones of lymph nodes as described above, reticular cells secrete interleukin-7 (IL-7). This is a cytokine critical for both the maintenance and survival of T cells. Link et al. (2007) demonstrated that when lymph nodes or reticular cell-derived IL-7 are disrupted, T cell survival decreases significantly. Additionally, these same reticular cells release CCL19, a chemokine that regulates T cell movement and also helps maintain overall T-cell well-being. The balance between these two signaling molecules ensures that T cells remain functional and ready to respond rapidly to presented antigens. Beyond just T cells, reticular cells are equally essential for B cell homeostasis. According to Cremasco et al. (2014), reticular cells produce BAFF (B-cell activating factor), a survival signal that helps to sustain B cell populations within lymphoid follicles. When reticular cells were experimentally removed, it was shown that B cell organization collapses.
Vortioxetine was invented by scientists at Lundbeck who reported the rationale and synthesis for the drug (then called Lu AA21004) in a 2011 paper. In 2007, the compound was in Phase II clinical trials, and Lundbeck and Takeda entered into a partnership in which Takeda paid Lundbeck $40 million up-front, with promises of up to $345 million in milestone payments, and Takeda agreed to pay most of the remaining cost of developing the drug. The companies agreed to co-promote the drug in the US and Japan, and that Lundbeck would receive a royalty on all such sales. The deal included another drug candidate, tedatioxetine (Lu AA24530), and could be expanded to include two other Lundbeck compounds. Vortioxetine was approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults in September 2013, and it was approved in the European Union in December 2013.
After passing the OBBBA, Congress needed to approve a new spending bill to fund the federal government beyond October 1, 2025, when the previous budget expired. The 53 Republican senators had to either eliminate the filibuster or convince at least seven Democrats to join them in order to reach the 60-vote supermajority required to advance their proposal. Most Democrats opposed the Republican plan and requested a compromise that would extend the healthcare subsidies cut by the OBBBA. The resulting stalemate triggered the 2025 United States federal government shutdown, which became the longest government shutdown in U.S. history.
Sources: en.wikipedia.org
=== Category:EC 1.8 (act on a sulfur group of donors) === Category:EC 1.8.1 (with NAD+ or NADP+ as acceptor) Glutathione reductase EC 1.8.1.7 Thioredoxin reductase EC 1.8.1.9 Category:EC 1.8.2 (with a cytochrome as acceptor) Category:EC 1.8.3 (with oxygen as acceptor) Sulfite oxidase EC 1.8.3.1 Category:EC 1.8.4 (with a disulfide as acceptor) Category:EC 1.8.5 (with a quinone or similar compound as acceptor) Category:EC 1.8.6 deleted, included in EC 2.5.1.18 Category:EC 1.8.7 (with an iron–sulfur protein as acceptor) Category:EC 1.8.98 (with other, known, acceptors) Category:EC 1.8.99 (with other acceptors)
==== Context ==== The formation of the third cabinet followed the resignation of Mirtha Vásquez on the eve of 31 January 2022. This occurred the day after the resignation of the Minister of the Interior, who resigned citing a “structural problem of corruption” and the impossibility of creating consensus. This decision triggered a political crisis, with the previously supportive Purple Party demanding the formation of a capable government or else the resignation of President Pedro Castillo. The third vice president of the Congress Patricia Chirinos (AvP) announced the filing of a motion of censure against the president, citing the "evident corruption of his government."
== Career == Cooks became an assistant professor at Kansas State University from 1968 to 1971. In 1971, he took a position at Purdue University. He became a professor of chemistry in 1980 and was appointed the Henry Bohn Hass Distinguished Professor in 1990. Cooks was co-editor of the Annual Review of Analytical Chemistry from 2013 to 2017.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.